372 related articles for article (PubMed ID: 29174814)
1. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
7. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
[TBL] [Abstract][Full Text] [Related]
8. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
11. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
18. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents.
Duan Y; Xu S; Xiong H; Wang L; Zhao B; Wang P; Wang C; Peng Y; Cai S; Luo R; Zheng P; Tang Q
Bioorg Med Chem Lett; 2018 Feb; 28(3):254-259. PubMed ID: 29317165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
